PPARG and RANBP9

Number of citations of the paper that reports this interaction (PubMedID 15604093)
54

Data Source:
HPRD (two hybrid)

		PPARG	RANBP9
Description		peroxisome proliferator activated receptor gamma	RAN binding protein 9
Image
GO Annotations	Cellular Component	Nuclear Chromatin Nucleus Nucleoplasm Cytosol Protein-containing Complex Intracellular Membrane-bounded Organelle Perinuclear Region Of Cytoplasm RNA Polymerase II Transcription Factor Complex	Ubiquitin Ligase Complex Nucleus Cytoplasm Cytosol Microtubule Associated Complex Plasma Membrane
	Molecular Function	Transcription Regulatory Region Sequence-specific DNA Binding RNA Polymerase II Regulatory Region Sequence-specific DNA Binding DNA-binding Transcription Factor Activity, RNA Polymerase II-specific RNA Polymerase II Repressing Transcription Factor Binding DNA-binding Transcription Repressor Activity, RNA Polymerase II-specific DNA Binding Chromatin Binding Double-stranded DNA Binding DNA-binding Transcription Factor Activity Steroid Hormone Receptor Activity Nuclear Receptor Activity Prostaglandin Receptor Activity Fatty Acid Binding Protein Binding Protein C-terminus Binding Transcription Factor Binding Drug Binding Zinc Ion Binding Lipid Binding Enzyme Binding Protein Phosphatase Binding Estrogen Receptor Binding Nuclear Receptor Transcription Coactivator Activity Activating Transcription Factor Binding Signaling Receptor Activity Peptide Binding Identical Protein Binding Sequence-specific DNA Binding Protein Self-association Transcription Regulatory Region DNA Binding Retinoid X Receptor Binding Arachidonic Acid Binding DBD Domain Binding LBD Domain Binding Alpha-actinin Binding E-box Binding Transcription Factor Activity, Direct Ligand Regulated Sequence-specific DNA Binding	Protein Binding Ran GTPase Binding Enzyme Binding
	Biological Process	Negative Regulation Of Transcription By RNA Polymerase II Placenta Development Negative Regulation Of Acute Inflammatory Response Regulation Of Transcription By RNA Polymerase II Transcription Initiation From RNA Polymerase II Promoter Lipid Metabolic Process Fatty Acid Metabolic Process Activation Of Cysteine-type Endopeptidase Activity Involved In Apoptotic Process Signal Transduction G Protein-coupled Receptor Signaling Pathway Multicellular Organism Development Heart Development Response To Nutrient Regulation Of Blood Pressure Response To Cold Response To Mechanical Stimulus Hormone-mediated Signaling Pathway Macrophage Derived Foam Cell Differentiation Negative Regulation Of Macrophage Derived Foam Cell Differentiation Negative Regulation Of Receptor Biosynthetic Process Negative Regulation Of Cholesterol Storage Negative Regulation Of Sequestering Of Triglyceride Long-chain Fatty Acid Transport Negative Regulation Of Angiogenesis Regulation Of Lipid Metabolic Process Fatty Acid Oxidation Cell Differentiation Monocyte Differentiation Negative Regulation Of Cell Growth Epithelial Cell Differentiation Response To Caffeine Animal Organ Regeneration Response To Nutrient Levels Response To Retinoic Acid Cellular Response To Insulin Stimulus Negative Regulation Of Collagen Biosynthetic Process Response To Vitamin A Response To Lipid Peroxisome Proliferator Activated Receptor Signaling Pathway Response To Immobilization Stress Glucose Homeostasis Response To Starvation Regulation Of Circadian Rhythm Lipoprotein Transport Positive Regulation Of DNA Binding Steroid Hormone Mediated Signaling Pathway Negative Regulation Of Blood Vessel Endothelial Cell Migration Response To Estrogen Innate Immune Response Cell Fate Commitment Positive Regulation Of Fat Cell Differentiation Low-density Lipoprotein Particle Receptor Biosynthetic Process Negative Regulation Of Transcription, DNA-templated Positive Regulation Of Transcription, DNA-templated Positive Regulation Of Fatty Acid Metabolic Process Positive Regulation Of Transcription By RNA Polymerase II Positive Regulation Of Fatty Acid Oxidation Cell Maturation Rhythmic Process Negative Regulation Of Smooth Muscle Cell Proliferation Positive Regulation Of Oligodendrocyte Differentiation Negative Regulation Of Inflammatory Response White Fat Cell Differentiation Positive Regulation Of DNA-binding Transcription Factor Activity Negative Regulation Of Telomerase Activity Lipid Homeostasis Positive Regulation Of Phagocytosis, Engulfment Negative Regulation Of Interferon-gamma-mediated Signaling Pathway Regulation Of Cholesterol Transporter Activity Regulation Of Transcription Involved In Cell Fate Commitment Negative Regulation Of Gene Silencing By MiRNA Pri-miRNA Transcription By RNA Polymerase II Cellular Response To Retinoic Acid Cellular Response To Vitamin E Cellular Response To Prostaglandin E Stimulus Cellular Response To Lipid Cellular Response To Low-density Lipoprotein Particle Stimulus Cellular Response To Hyperoxia Response To Metformin Negative Regulation Of Vascular Smooth Muscle Cell Proliferation Positive Regulation Of Vascular Associated Smooth Muscle Cell Apoptotic Process Negative Regulation Of Vascular Endothelial Cell Proliferation Negative Regulation Of Pancreatic Stellate Cell Proliferation	MAPK Cascade Microtubule Nucleation Axon Guidance Protein-containing Complex Assembly Negative Regulation Of ERK1 And ERK2 Cascade
Pathways		PPARA activates gene expression Transcriptional regulation of white adipocyte differentiation Transcriptional regulation of white adipocyte differentiation Nuclear Receptor transcription pathway SUMOylation of intracellular receptors Regulation of PTEN gene transcription Regulation of PTEN gene transcription MECP2 regulates transcription factors	L1CAM interactions RAF/MAP kinase cascade MET activates RAS signaling
Drugs		Alpha-Linolenic Acid Icosapent Troglitazone Mesalazine Valproic Acid Indomethacin Rosiglitazone Fenoprofen Nateglinide Sulfasalazine Repaglinide Telmisartan Balsalazide Fenofibrate Ibuprofen Glipizide Amiodarone Pioglitazone Mitiglinide Bezafibrate Flufenamic Acid Resveratrol Phthalic Acid Capric acid Doconexent Oleic Acid (S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid 2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID Reglixane Elafibranor T131 CLX-0921 (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid 2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid (5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid (8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid (8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID 3-(5-methoxy-1H-indol-3-yl)propanoic acid Indeglitazar (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid 2-chloro-5-nitro-N-phenylbenzamide (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid 3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE Triclosan (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid Aleglitazar Clinofibrate Lobeglitazone Ciglitazone Dexibuprofen Omega-3 fatty acids Curcumin Arhalofenate
Diseases		Type II diabetes mellitus Familial partial lipodystrophy (FPL), including the following four diseases: Kobberling-type lipodystrophy (FPLD1); Dunnigan-type lipodystrophy (FPLD2); Dunnigan-like lipodystrophy (FPLD3); AKT2 associated lipodystrophy Thyroid cancer
GWAS		Arterial stiffness index ( 31235810) Body mass index ( 28892062 25673413 29273807) Cholesterol, total ( 25961943) Drug-induced liver injury ( 22968431) Endometrial cancer ( 30093612) Endometrial cancer (endometrioid histology) ( 30093612) Eosinophil counts ( 27863252) Eosinophil percentage of granulocytes ( 27863252) Eosinophil percentage of white cells ( 27863252) Fasting blood insulin ( 25631608) Fasting blood insulin (BMI interaction) ( 22581228) Fasting blood insulin adjusted for BMI ( 25625282) Gut microbiota (functional units) ( 27694959) HDL cholesterol ( 30275531) Heel bone mineral density ( 30598549) Hematocrit ( 27863252) Hemoglobin concentration ( 27863252) High density lipoprotein cholesterol levels ( 29403010) Hip circumference adjusted for BMI ( 25673412) Idiopathic osteonecrosis of the femoral head ( 31135556) LDL cholesterol ( 25961943) LDL cholesterol levels ( 30698716) LDL cholesterol levels in current drinkers ( 30698716) LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df) ( 30698716) LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df) ( 30698716) Medication use (drugs used in diabetes) ( 31015401) Medication use (HMG CoA reductase inhibitors) ( 31015401) Medication use (thyroid preparations) ( 31015401) Modified Stumvoll Insulin Sensitivity Index (model adjusted for BMI) ( 27416945) Neutrophil percentage of granulocytes ( 27863252) Plasminogen activator inhibitor type 1 levels (PAI-1) ( 22990020) Platelet count ( 29403010) Potassium levels ( 29403010) Sexual dimorphism in anthropometric traits ( 23754948) Systemic lupus erythematosus ( 28714469) Type 2 diabetes ( 22885922 18372903 24509480 30054458 29358691 30297969 29632382 31118516 20581827 17463246 30718926 17463248 17463249 28869590) Type 2 diabetes (adjusted for BMI) ( 29632382) Waist circumference ( 31453325) Waist circumference variance ( 31453325) Waist-hip ratio ( 25673412) Waist-to-hip ratio adjusted for BMI ( 26426971) Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour) ( 28443625) Waist-to-hip ratio adjusted for BMI (age <50) ( 26426971) Waist-to-hip ratio adjusted for BMI (age >50) ( 26426971) Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction) ( 28448500) Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction) ( 28443625) Waist-to-hip ratio adjusted for BMI in active individuals ( 28448500) Waist-to-hip ratio adjusted for BMI in non-smokers ( 28443625) Waist-to-hip ratio adjusted for BMI x sex x age interaction (4df test) ( 26426971) Waist-to-hip ratio adjusted for body mass index ( 25673412 28448500)	Breast cancer ( 29059683 23535729)
Interacting Genes		106 interacting genes: ALOX15B ANP32A APP BCAS2 BRD8 CDC34 CDK5 CEP350 CNOT1 COPS5 CREBBP DNTTIP2 EDF1 EGFR FABP1 FHOD1 FOXO1 GADD45B GADD45G GRIP1 HDAC1 HDAC3 HDAC4 HELZ2 HMGA1 IGFBP3 IKBKB JAZF1 JMJD1C JUN JUND KAT2A KAT5 KCTD13 KIF11 KIF1A KLF5 LMO4 LRIF1 MAFF MAP2K1 MAPK1 MAPK8 MED1 MED24 MFHAS1 MIF4GD MSX2 MUC1 NCOA1 NCOA2 NCOA3 NCOA4 NCOA6 NCOR1 NCOR2 NFE2L2 NFE2L3 NFKB1 NFKBIB NR0B1 NR0B2 NR2E3 NR4A1 NR4A2 NRIP1 NSD1 PAK4 PDIA2 PHB2 PML POU1F1 PPARGC1A PPM1B PRKCA RAD54L2 RANBP9 RB1 RELA ROBO4 RXRA RXRB RXRG SERPINH1 SFPQ SIRT1 SMARCD3 STAT6 STUB1 SVIL SYT1 TFAP2A TNP1 TRIM24 TRIP4 UBC UBE2I USP7 VDR ZBTB20 ZBTB3 ZBTB5 ZBTB9 ZNF496 ZNHIT3 ZSCAN1	56 interacting genes: ADAP1 ADAP2 APC AR ATM AXL BACE1 BRCA1 CACNA1G CALB1 CBS CCND1 CDK11B CLEC7A DDX4 DISC1 DYRK1B ENTPD1 ESR1 EXOC2 FMR1 HIPK2 HMBS HNF4G ITGAL ITGB2 L1CAM LMNA MAPK6 MET MKLN1 MPHOSPH8 NCOA6 NCOR2 PPARD PPARG PPP1CA PRKACA RAF1 RAN S100A7 SMAD2 SMAD3 SMAD9 SOS1 SPOP SPP1 TFRC THRA THRB TP53 TP73 UCHL1 USP11 WNK1 YPEL5
Entrez ID		5468	10048
HPRD ID		03288	04835
Ensembl ID		ENSG00000132170	ENSG00000010017
Uniprot IDs		A0A494C1F9 D2KUA6 E9PFX5 P37231	A0A024QZW3 Q96S59
PDB IDs		1FM6 1FM9 1I7I 1K74 1KNU 1NYX 1PRG 1RDT 1WM0 1ZEO 1ZGY 2ATH 2F4B 2FVJ 2G0G 2G0H 2GTK 2HFP 2HWQ 2HWR 2I4J 2I4P 2I4Z 2OM9 2P4Y 2POB 2PRG 2Q59 2Q5P 2Q5S 2Q61 2Q6R 2Q6S 2Q8S 2QMV 2VSR 2VST 2VV0 2VV1 2VV2 2VV3 2VV4 2XKW 2YFE 2ZK0 2ZK1 2ZK2 2ZK3 2ZK4 2ZK5 2ZK6 2ZNO 2ZVT 3ADS 3ADT 3ADU 3ADV 3ADW 3ADX 3AN3 3AN4 3B0Q 3B0R 3B1M 3B3K 3BC5 3CDP 3CDS 3CS8 3CWD 3D6D 3DZU 3DZY 3E00 3ET0 3ET3 3FEJ 3FUR 3G9E 3GBK 3H0A 3HO0 3HOD 3IA6 3K8S 3KMG 3LMP 3NOA 3OSI 3OSW 3PBA 3PO9 3PRG 3QT0 3R5N 3R8A 3R8I 3S9S 3SZ1 3T03 3TY0 3U9Q 3V9T 3V9V 3V9Y 3VJH 3VJI 3VN2 3VSO 3VSP 3WJ4 3WJ5 3WMH 3X1H 3X1I 4A4V 4A4W 4CI5 4E4K 4E4Q 4EM9 4EMA 4F9M 4FGY 4HEE 4JAZ 4JL4 4L96 4L98 4O8F 4OJ4 4PRG 4PVU 4PWL 4R06 4R2U 4R6S 4XLD 4XTA 4XUH 4XUM 4Y29 4YT1 5AZV 5DSH 5DV3 5DV6 5DV8 5DVC 5DWL 5F9B 5GTN 5GTO 5GTP 5HZC 5JI0 5LSG 5TTO 5TWO 5U5L 5UGM 5WQX 5WR0 5WR1 5Y2O 5Y2T 5YCN 5YCP 5Z5S 5Z6S 6AD9 6AN1 6AUG 6AVI 6C1I 6C5Q 6C5T 6D3E 6D8X 6D94 6DBH 6DCU 6DGL 6DGO 6DGP 6DGQ 6DGR 6DH9 6DHA 6E5A 6ENQ 6F2L 6FZF 6FZG 6FZJ 6FZP 6FZY 6ICJ 6IJR 6IJS 6ILQ 6IZM 6IZN 6JQ7 6K0T 6MCZ 6MD0 6MD1 6MD2 6MD4 6MS7 6O67 6O68	5JI7 5JI9 5JIU
Enriched GO Terms of Interacting Partners?
Tagcloud ?
Tagcloud (Difference) ?
Tagcloud (Intersection) ?